% | $
Quotes you view appear here for quick access.

Qiagen NV Message Board

  • pieightyeight pieightyeight Apr 4, 2011 6:39 PM Flag

    QIAGEN to Acquire Cellestis

    QIAGEN Makes Proposal to Acquire Australian Diagnostics Company Cellestis Limited
    -- QIAGEN to acquire Cellestis Limited (CST:AU) via a Scheme of Arrangement (the Scheme) for approximately A$341 million(1) (US$355 million), or A$3.55 per share
    -- Unanimous support from Cellestis board of directors(2);
    QIAGEN granted options to acquire up to 19.9% of Cellestis ordinary shares under certain circumstances, subject to regulatory approvals
    -- Acquisition provides QIAGEN with exclusive access to QuantiFERON® technology for high sensitivity, early disease detection not possible with other diagnostic approaches
    -- QuantiFERON® technology successfully commercialized with two marketed Cellestis tests for detection of latent tuberculosis (TB) and life-threatening CMV virus
    -- QIAGEN to expand QuantiFERON® portfolio, migrate technology to QIAsymphony and QIAensemble platforms and leverage synergies with current QIAGEN assay portfolio and pipeline
    -- Acquisition would accelerate QIAGEN's sales and adjusted EPS growth rates in 2012

    SortNewest  |  Oldest  |  Most Replied Expand all replies
26.88+0.38(+1.43%)Nov 27 1:00 PMEST